Home › Funds › Nicholas Investment Partners, LP › ELVN
Nicholas Investment Partners, LP position in ELVN
ENLIVEN THERAPEUTICS INC · Health Care
Nicholas Investment Partners, LP reported holding 549,190 shares of ELVN (ENLIVEN THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$25.2M, representing 1.89% of its reported portfolio and ranking #4 among its reported holdings. Nicholas Investment Partners, LP has disclosed ELVN holdings in 6 of the last 10 reported quarters, going back to Q2 2024.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Nicholas Investment Partners, LP's ELVN position evolved
Nicholas Investment Partners, LP first disclosed a stake in ELVN in Q2 2024 at 56,072 shares (US$1.3M). The position peaked in Q3 2026 at 549,190 shares, worth US$25.2M. Across 6 filings, Nicholas Investment Partners, LP increased the stake 3 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 549,190 shares valued at US$25.2M — an increase of 157,661 shares quarter over quarter.. Notable position changes include a 210% increase in Q3 2024 (shares fell 12% over the following quarter), a 114% increase in Q2 2026 (shares fell 10% over the following quarter), a 40% increase in Q3 2026 (shares rose 6% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 56.07K | $1.31M | New |
| Q3 2024 | 173.75K | $4.44M | Add |
| Q4 2024 | 157.63K | $3.55M | Reduce |
| Q1 2026 | 182.73K | $7.16M | New |
| Q2 2026 | 391.53K | $19.87M | Add |
| Q3 2026 | 549.19K | $25.17M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ELVN and 13F data
ELVN (ENLIVEN THERAPEUTICS INC) is a Health Care company. 61 other funds we track also report a position in ELVN — the largest reported positions include ORBIMED ADVISORS LLC (US$343.9M), Polar Capital Holdings Plc (US$294.5M), Vestal Point Capital, LP (US$203.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ELVN
- ORBIMED ADVISORS LLC 6.78M sh · $343.91M · Q2 2026
- Polar Capital Holdings Plc 6.43M sh · $294.53M · Q3 2026
- Vestal Point Capital, LP 4.00M sh · $203.00M · Q2 2026
- Commodore Capital LP 3.27M sh · $166.21M · Q2 2026
- Fairmount Funds Management LLC 1.86M sh · $94.17M · Q2 2026
- Bellevue Group AG 1.49M sh · $75.62M · Q2 2026
- First Light Asset Management, LLC 1.36M sh · $69.06M · Q2 2026
- Siren, L.L.C. 1.48M sh · $67.62M · Q3 2026
- Novo Holdings A/S 1.00M sh · $50.75M · Q2 2026
- Logos Global Management LP 1.08M sh · $49.51M · Q3 2026
- BAKER BROS. ADVISORS LP 905.19K sh · $45.94M · Q2 2026
- First Turn Management, LLC 958.70K sh · $43.95M · Q3 2026
More on Nicholas Investment Partners, LP
FAQ
How long has Nicholas Investment Partners, LP held ELVN?
Nicholas Investment Partners, LP has disclosed ELVN holdings in 6 of the last 10 reported quarters, going back to Q2 2024.
What is Nicholas Investment Partners, LP's current position in ELVN?
As of Q3 2026, Nicholas Investment Partners, LP holds 549.19K shares of ELVN (ENLIVEN THERAPEUTICS INC), valued at $25.17M, representing 1.89% of its reported portfolio and ranking #4.
Has Nicholas Investment Partners, LP been buying or selling ELVN?
In the latest 13F filing (Q3 2026), Nicholas Investment Partners, LP increased its position in ELVN. The position peaked in Q3 2026 at 549.19K shares.
Which other funds hold ELVN?
Other major institutional holders of ELVN include ORBIMED ADVISORS LLC, Polar Capital Holdings Plc, Vestal Point Capital, LP, among 61 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.